Patients who signed the prescreening consent form
N=716

Failed quality check of the tumor tissue
N=13

Tissue samples analyzed
N=703

Patients molecularly eligible
N=204

Patients non molecularly eligible
N=499

Patients not enrolled
N=62
Did not meet the eligibility criteria (n = 36)
Medical decision (n = 9)
Death (n = 8)
Clinical deterioration (n = 4)
Other treatment ongoing (n = 3)
Patient decision (n = 2)

Patients enrolled
N=142

Patients did not enter Part I
N=7
Medical decision/study closure (n = 4)
Death (n = 2)
Patient decision (n = 1)

Patients started Part I TMZ priming
N=135

Patients who did not start Part II
N=102
Radiologic or clinical disease progression (n = 95)
Death (n = 6)
Patient decision (n = 1)

Patients who started Part II immunotherapy
N=33
Discontinued for disease progression (n = 23)
Discontinued for death (n = 3)
Discontinued for adverse event (n = 1)
Discontinued for Patient/Medical decision (n = 6)